文献速递生殖医学

Eggsurance?一项关于选择性卵子冷冻决策辅助工具的随机对照试验

Eggsurance? A randomized controlled trial of a decision aid for elective egg freezing.
PubMed 文献 · Hum Reprod · 2024-01-01

这项单盲、两组平行随机对照试验纳入306名考虑选择性卵子冷冻的女性,评估在线决策辅助工具对决策冲突等结局的影响。12个月时干预组决策冲突评分显著低于对照组,6个月时决策准备度显著更高,两组在痛苦、知识、是否做出决定、知情选择和决策后悔方面无显著差异。

要点

  • 决策辅助工具在12个月时降低决策冲突评分(均差-6.99,95%CI -12.96至-1.02,P=0.022)。
  • 决策辅助工具在6个月时提高决策准备度评分(均差9.22,95%CI 2.35至16.08,P=0.009)。
  • 12个月时两组在痛苦、知识、是否做出决定、知情选择和决策后悔方面无显著差异。

核心结论

  • 决策辅助工具降低决策冲突、帮助女性为决策做准备,且不引起痛苦。
  • 这是首个评估选择性卵子冷冻决策辅助工具的随机对照试验,该工具将公开提供并可针对国际使用进行调整。

研究设计与样本

  • 单盲、两组平行随机对照试验,目标样本量286人,实际随机306人(干预组150人,对照组156人)。
  • 随机化按1:1分配至对照组(现有网站信息)或干预组(决策辅助工具加现有网站信息),按澳大利亚州/领地和既往IVF专家咨询分层。
  • 研究对象为居住澳大利亚、考虑选择性卵子冷冻、英语熟练且能上网的18岁及以上女性,于2020年9月至2021年3月招募,结局记录12个月,数据收集于2022年3月完成。
  • 主要结局为决策冲突(决策冲突量表),其他结局包括痛苦(抑郁焦虑压力量表)、知识、是否做出决定、决策准备度、知情选择和决策后悔。

主要发现

  • 12个月时,调整基线决策冲突后,干预组决策冲突量表评分显著低于对照组(均差-6.99,95%CI -12.96至-1.02,P=0.022)。
  • 6个月时,干预组对选择性卵子冷冻的决策准备度显著高于对照组(均差9.22,95%CI 2.35至16.08,P=0.009)。
  • 12个月时,两组在痛苦(均差0.61,95%CI -3.72至4.93,P=0.783)、知识(均差0.23,95%CI -0.21至0.66,P=0.309)和是否做出决定(相对风险1.21,95%CI 0.90至1.64,P=0.212)方面无显著差异。
  • 12个月时已做出决定的参与者中(干预组48人,对照组45人),两组在知情选择(相对风险1.00,95%CI 0.81至1.25,P=0.983)和决策后悔(中位评分差-5.00,95%CI -15.30至5.30,P=0.337)方面无显著差异。

临床怎么用

  • 作者认为决策辅助工具可降低决策冲突并改善女性决策准备度,该工具将公开提供并可针对国际使用进行调整。

局限性

  • 参与者 uptake 未知,且招募方法及 coronavirus disease 2019 大流行导致的限制可能造成采样偏倚。
  • 部分结局样本量小,限制了推断。
  • 使用研究特异性或改编的验证量表可能影响部分结果的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does a purpose-designed Decision Aid for women considering elective egg freezing (EEF) impact decisional conflict and other decision-related outcomes? SUMMARY ANSWER: The Decision Aid reduces decisional conflict, prepares women for decision-making, and does not cause distress. WHAT IS ALREADY KNOWN: Elective egg-freezing decisions are complex, with 78% of women reporting high decisional conflict. Decision Aids are used to support complex health decisions. We developed an online Decision Aid for women considering EEF and demonstrated that it was acceptable and useful in Phase 1 testing. STUDY DESIGN, SIZE, DURATION: A single-blind, two-arm parallel group randomized controlled trial was carried out. Target sample size was 286 participants. Randomization was 1:1 to the control (existing website information) or intervention (Decision Aid plus existing website information) group and stratified by Australian state/territory and prior IVF specialist consultation. Participants were recruited between September 2020 and March 2021 with outcomes recorded over 12 months. Data were collected using online surveys and data collection was completed in March 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Females aged ≥18 years, living in Australia, considering EEF, proficient in English, and with internet access were recruited using multiple methods including social media posts, Google advertising, newsletter/noticeboard posts, and fertility clinic promotion. After completing the baseline survey, participants were emailed their allocated website link(s). Follow-up surveys were sent at 6 and 12 months. Primary outcome was decisional conflict (Decisional Conflict Scale). Other outcomes included distress (Depression Anxiety and Stress Scale), knowledge about egg freezing and female age-related infertility (study-specific measure), whether a decision was made, preparedness to decide about egg freezing (Preparation for Decision-Making Scale), informed choice (Multi-Dimensional Measure of Informed Choice), and decision regret (Decision Regret Scale). MAIN RESULTS AND THE ROLE OF CHANCE: Overall, 306 participants (mean age 30 years; SD: 5.2) were randomized (intervention n = 150, control n = 156). Decisional Conflict Scale scores were significantly lower at 12 months (mean score difference: -6.99 [95% CI: -12.96, -1.02], P = 0.022) for the intervention versus control group after adjusting for baseline decisional conflict. At 6 months, the intervention group felt significantly more prepared to decide about EEF than the control (mean score difference: 9.22 [95% CI: 2.35, 16.08], P = 0.009). At 12 months, no group differences were observed in distress (mean score difference: 0.61 [95% CI: -3.72, 4.93], P = 0.783), knowledge (mean score difference: 0.23 [95% CI: -0.21, 0.66], P = 0.309), or whether a decision was made (relative risk: 1.21 [95% CI: 0.90, 1.64], P = 0.212). No group differences were found in informed choice (relative risk: 1.00 [95% CI: 0.81, 1.25], P = 0.983) or decision regret (median score difference: -5.00 [95% CI: -15.30, 5.30], P = 0.337) amongst participants who had decided about EEF by 12 months (intervention n = 48, control n = 45). LIMITATIONS, REASONS FOR CAUTION: Unknown participant uptake and potential sampling bias due to the recruitment methods used and restrictions caused by the coronavirus disease 2019 pandemic. Some outcomes had small sample sizes limiting the inferences made. The use of study-specific or adapted validated measures may impact the reliability of some results. WIDER IMPLICATIONS OF THE FINDINGS: This is the first randomized controlled trial to evaluate a Decision Aid for EEF. The Decision Aid reduced decisional conflict and improved women's preparation for decision making. The tool will be made publicly available and can be tailored for international use. STUDY FUNDING/COMPETING INTEREST(S): The Decision Aid was developed with funding from the Royal Women's Hospital Foundation and McBain Family Trust. The study was funded by a National Health and Medical Research Council (NHMRC) Project Grant APP1163202, awarded to M. Hickey, M. Peate, R.J. Norman, and R. Hart (2019-2021). S.S., M.P., D.K., and S.B. were supported by the NHMRC Project Grant APP1163202 to perform this work. R.H. is Medical Director of Fertility Specialists of Western Australia and National Medical Director of City Fertility. He has received grants from MSD, Merck-Serono, and Ferring Pharmaceuticals unrelated to this study and is a shareholder of CHA-SMG. R.L. is Director of Women's Health Melbourne (Medical Practice), ANZSREI Executive Secretary (Honorary), RANZCOG CREI Subspecialty Committee Member (Honorary), and a Fertility Specialist at Life Fertility Clinic Melbourne and Royal Women's Hospital Public Fertility Service. R.A.A. has received grants from Ferring Pharmaceuticals unrelated to this study. M.H., K.H., and R.J.N. have no conflicts to declare. TRIAL REGISTRATION NUMBER: ACTRN12620001032943. TRIAL REGISTRATION DATE: 11 August 2020. DATE OF FIRST PATIENT’S ENROLMENT: 29 September 2020.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sandhu S, Hickey M, Koye DN, et al. Eggsurance? A randomized controlled trial of a decision aid for elective egg freezing. Hum Reprod. 2024. PMID: 38876980. doi:10.1093/humrep/deae121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。